id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1998-D-0021-0008,FDA,FDA-1998-D-0021,ANDAs: Impurities in Drug Substances- Guidance for Industry,Other,Guidance,2009-07-15T04:00:00Z,2009,7,2009-07-15T04:00:00Z,,2020-05-12T17:05:58Z,,0,0,09000064809f1f49
FDA-1998-D-0021-0006,FDA,FDA-1998-D-0021,SEE FDA-1998-D-0021-0007,Notice,NAD-Notice of Availability of Data,2009-07-15T04:00:00Z,2009,7,2009-07-15T04:00:00Z,,2009-07-15T16:49:49Z,E9-16868,0,0,09000064809f1cd4
FDA-1998-D-0021-0007,FDA,FDA-1998-D-0021,Guidance for Industry on Abbreviated New Drug Applications: Impurities in Drug Substances; Availability,Notice,Notice of Availability,2009-07-15T04:00:00Z,2009,7,2009-07-15T04:00:00Z,,2020-05-12T17:04:06Z,E9-16868,0,0,09000064809f1620
FDA-1998-D-0021-0003,FDA,FDA-1998-D-0021,Guidance,Supporting & Related Material,GDL-Guidance,2005-02-01T05:00:00Z,2005,2,,,2008-05-16T21:18:01Z,,0,0,09000064805640bc
FDA-1998-D-0021-0004,FDA,FDA-1998-D-0021,Guidance,Supporting & Related Material,GDL-Guidance,2005-02-01T05:00:00Z,2005,2,,,2008-05-16T21:18:00Z,,0,0,09000064805640bf
FDA-1998-D-0021-0005,FDA,FDA-1998-D-0021,FDA,Notice,NAD-Notice of Availability of Data,2005-02-01T05:00:00Z,2005,2,2005-01-31T05:00:00Z,2005-05-03T03:59:59Z,2008-05-16T21:18:00Z,,0,0,09000064805640c1
FDA-1998-D-0021-0002,FDA,FDA-1998-D-0021,FDA,Notice,NAD-Notice of Availability of Data,1999-12-15T05:00:00Z,1999,12,,,2008-05-16T21:18:01Z,,0,0,09000064805640ba
FDA-1998-D-0021-0001,FDA,FDA-1998-D-0021,FDA,Notice,NEC-Notice of Extension,1998-10-20T04:00:00Z,1998,10,1998-10-20T04:00:00Z,1998-11-24T04:59:59Z,2008-05-16T21:18:01Z,,0,0,0900006480564036